Results 131 to 140 of about 94,577 (347)

Designer drugs – outside the law but still a problem [PDF]

, 2018
Rob Munro
openalex   +1 more source

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

Knowledge, attitudes, and practices of Chinese college students towards novel psychoactive substances

BMC Public Health
Background This study aimed to investigate the knowledge, attitudes, and practices (KAP) among Chinese college students regarding novel psychoactive substances (NPS), where practices specifically refer to behaviors related to NPS access and usage ...
Liqin Lu, Xinhao Zhou, Jue Deng, Binling Zhu, Liang Meng, Xianghui Lai, Xiaoli Zhu   +6 more
doaj   +1 more source

Designer Cellular Spheroids with DNA Origami for Drug Screening [PDF]

, 2023
Hao Pei, Jiayi Wei, Yueyang Sun, Heming Wang, Tong Zhu, Li Li, Ying Zhou, Quan Liu, Zhen Dai, Wenjuan Li, Taihua Yang, Bingmei Wang, Changfeng Zhu, Xizhong Shen, Qunyan Yao, Guangqi Song, Yicheng Zhao   +16 more
openalex   +1 more source

Fast Times in Federal Court and the Need for Flexibility [PDF]

, 2018
The shifting landscape of criminal prosecutions involving designer drugs presents several novel legal issues. There are different ways to address these issues when they are the result of the production, possession, or distribution of as-of-yet ...
Moore, K. Michael
core   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

A review of temporal interference, nanoparticles, ultrasound, gene therapy, and designer receptors for Parkinson disease

npj Parkinson's Disease
In this review, we summarize preclinical and clinical trials investigating innovative neuromodulatory approaches for Parkinson disease (PD) motor symptom management.
A. D. Currie, J. K. Wong, M. S. Okun
doaj   +1 more source

Determinação de designer drugs em saliva por paper spray mass spectrometry

Química Nova
Determination of two drugs of abuse in saliva has been performed by Paper Spray Ionization Mass Spectrometry (PSI-MS) using a Molecularly Imprinted Polymer (MIP) coated paper as substrate.
Lanaia Ítala L. Maciel, Thays C. Carvalho, Igor Pereira, Boniek G. Vaz   +3 more
doaj   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

The synthetic cannabinoids menace: a review of health risks and toxicity

European Journal of Medical Research
Synthetic cannabinoids (SCs) are chemically classified as psychoactive substances that target the endocannabinoid system in many body organs. SCs can initiate pathophysiological changes in many tissues which can be severe enough to damage the normal ...
Ayman Alzu’bi, Fatimah Almahasneh, Ramada Khasawneh, Ejlal Abu-El-Rub, Worood Bani Baker, Raed M. Al-Zoubi   +5 more
doaj   +1 more source